Sponsor & Developer Portfolio

Sinovac

Clinical development pipeline, platform architecture, and registered trial tracking for Sinovac vaccine candidates.

Candidates

Target Diseases

Linked Studies

Development Phase Distribution

Phase 3 Clinical Trial: 13 Discontinued / Inactive: 5 Phase 2 Clinical Trial: 2 Phase 1 Clinical Trial: 2

Platform Technologies

Inactivated: 8 Biological (unspecified platform): 6 Live attenuated: 3 Conjugate vaccine: 3 mRNA: 2

Target Pathogens & Indications

COVID-19 Hand, Foot, and Mouth Disease（HFMD) Hepatitis A Infection, Viral, Enterovirus Influenza Measles / Mumps / Rubella Meningococcal disease Pneumococcal disease Polio RSV Rabies Rotavirus Varicella / Zoster

Vaccine Pipeline Candidates (22)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

View Global Pipeline Matrix →

Discontinued / Inactive ctgov-400-u-ev71-vaccine-with-adjuvant-sinovac-biotech-co-ltd

400 U EV71 vaccine with adjuvant

Target: Infection, Viral, Enterovirus

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2011-11 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-covid-19-vaccine-vero-cell-inactivated-medium-dose-sinovac-resea

COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)

Target: COVID-19

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2022-03-10 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-experimental-vaccine-1-sinovac-research-and-development-co-ltd

Experimental vaccine 1

Target: COVID-19

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2023-03-20 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-medium-dosage-covid-19-vaccine-inactivated-sinovac-research-and-

High-dosage COVID-19 Vaccine,Inactivated

Target: COVID-19

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2023-02-20 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-medium-dose-covid-19-vaccine-vero-cell-inactivated-sinovac-resea

High-dose COVID-19 Vaccine(Vero Cell),Inactivated

Target: COVID-19

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2023-01-15 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-low-dose-rsv-mrna-vaccine-sinovac-biotech-co-ltd

Low-dose RSV mRNA vaccine

Target: RSV

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-06-30 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-high-dose-group-acyw135x-meningococcal-conjugate-vaccine-sinovac

low-dose Group ACYW135X Meningococcal Conjugate Vaccine

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2026-09-10 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-low-dose-experimental-vaccine-sinovac-biotech-co-ltd

Active-controlled vaccine A

Target: Varicella / Zoster

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2026-05-31 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-oral-hexavalent-reassortant-rotavirus-attenuated-live-vaccine-si

Oral hexavalent reassortant rotavirus attenuated live vaccine

Target: Rotavirus

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-06-15 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-2wipv-1sipv-sinovac-biotech-co-ltd

3wIPV

Target: Polio

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2026-09-08 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-bivalent-enterovirus-vaccine-vero-cell-inactivated-sinovac-biote

Enterovirus Type 71 Vaccine (Vero Cell), Inactivated

Target: Hand, Foot, and Mouth Disease（HFMD)

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2025-11-30 (registry estimate)

View Full Clinical Profile →

Phase 3 Clinical Trial ctgov-healive-hepatitis-a-vacine-human-diploid-cell-inactivated-sinova

Healive (hepatitis A vacine(human diploid cell), inactivated)

Target: Hepatitis A

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2028-03-17 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-live-attenuated-varicella-vaccine-sinovac-dalian-vaccine-technol

Live Attenuated Varicella Vaccine

Target: Varicella / Zoster

Platform: Live attenuated

Key Milestone: Primary completion (most advanced trial): 2028-12 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-provarix-sinovac-dalian-vaccine-technology-co-ltd

PROVARIX

Target: Varicella / Zoster

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-07-15 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-investigational-live-attenuated-varicella-vaccine-sinovac-dalian

Placebo (Freeze Dired Dilution)

Target: Varicella / Zoster

Platform: Live attenuated

Key Milestone: Primary completion (most advanced trial): 2021-12-19 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-sinovac-pcv13-sinovac-life-sciences-co-ltd

Prevnar®

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2026-05-12 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-sinovac-rabies-vaccine-sinovac-biotech-co-ltd

Sinovac rabies vaccine

Target: Rabies

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-09-30 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-vaicella-vaccine-dtap-on-day-0-mmr-on-day-30-sinovac-dalian-vacc

Varicella Vaccine

Target: Measles / Mumps / Rubella

Platform: Live attenuated

Key Milestone: Primary completion (most advanced trial): 2025-12 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-participants-will-receive-one-dose-of-vaccine-0-5-ml-of-sinovac-

Vaxigrip QIV

Target: Influenza

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2026-03 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-rabies-vaccine-serum-free-vero-cell-freeze-dried-sinovac-biotech

Verorab®

Target: Rabies

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-12-30 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-experimental-vaccine-sinovac-biotech-co-ltd

experimental vaccine

Target: Meningococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2026-11 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-sipv-sinovac-biotech-co-ltd

sIPV

Target: Polio

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-04-11 (registry estimate)

View Full Clinical Profile → Disease Hub →

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →